1
SECURITIES AND EXCHANGE COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: December 17, 1996
Atrix Laboratories, Inc.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18231 84-1043826
-------------- ------------ -------------------
(State of (Commission (IRS Employer
incorporation) File Number) Identification No.)
2579 Midpoint Drive, Fort Collins, Colorado 80525
----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (970) 482-5868
Not Applicable
--------------
(Former Name or Former Address, if Change Since Last Report)
2
Item 5. Other Events.
See the Press Release attached hereto as Exhibit 20.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
10 Agreement between the Registrant and Block Drug
Corporation dated December 16, 1996 **
20 Press Release dated December 17, 1996 regarding
agreement with Block Drug Company *
__________________________________
* Previously filed.
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment. The omitted portions have been separately filed with
the Securities and Exchange Commission.
3
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ATRIX LABORATORIES, INC.
Date: May 18, 1998 By: /s/ Brian Richmond
-----------------------------------
Brian Richmond, Vice President,
Finance and Assistant Secretary
4
EXHIBIT INDEX
Exhibit No. Exhibit Description
- ----------- -------------------
10 Agreement between the Registrant and Block Drug Corporation dated December 16, 1996**
20 Press Release dated December 17, 1996 regarding agreement with Block Drug Company*
__________________________________
* Previously filed.
** Certain portions of this Exhibit have been omitted based upon a request for
confidential treatment. The omitted portions have been separately filed with
the Securities and Exchange Commissions.